Actelion Ltd. lost almost one-quarter of its value Monday following news that it halted a Phase III trial of its drug for acute heart failure, Veletri, after an interim analysis indicated that it would fail to attain its primary endpoints.
Actelion Ltd. lost almost one-quarter of its value Monday following news that it halted a Phase III trial of its drug for acute heart failure, Veletri, after an interim analysis indicated that it would fail to attain its primary endpoints.
